Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Klinik dan Riset Kesehatan
Haitsam, Muhamad
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
RETINOPATI DIABETIK: PATOGENESIS, DIAGNOSIS, TATALAKSANA KINI DAN MASA DEPAN Ulfayani, Nabila; Haitsam, Muhamad
Jurnal Klinik dan Riset Kesehatan Vol 3 No 1 (2023): Edisi Oktober
Publisher : RSUD Dr. Saiful Anwar Province of East Java

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jk-risk.03.1.4

Abstract

Retinopati Diabetik (RD) merupakan penyebab utama kebutaan pada usia produktif di seluruh dunia. Kontrol hiperglikemi dan tekanan darah yang buruk merupakan faktor risiko yang esensial dalam perkembangan RD. Kondisi ini akan memicu terjadinya mekanisme biomolekular yang menyebabkan kerusakan pada pembuluh dan sel di retina dan berkembang menjadi RD. Tahap awal RD umumnya tidak bergejala, sehingga direkomendasikan untuk melakukan penapisan RD segera setelah pasien terdiagnosis DM tipe 2, dan setiap 5 tahun bagi pasien DM tipe 1. Diagnosis RD didasarkan oleh temuan lesi retina yang diklasifikasikan menjadi RD non proliferatif dan proliferatif, dan edema makula diabetik. Terapi RD dapat dilakukan dengan pendekatan non-farmakologi dan farmakologi yang diterapkan berdasarkan derajat keparahan untuk meminimalisir progresivitas RD. Selain terapi konvensional, terdapat terapi potensial di masa depan, yaitu mencakup terapi farmakologi secara oral, terapi genetik, terapi sel punca, dan terapi CRISPR-Cas-Based.
RETINOPATI DIABETIK: PATOGENESIS, DIAGNOSIS, TATALAKSANA KINI DAN MASA DEPAN Ulfayani, Nabila; Haitsam, Muhamad
Jurnal Klinik dan Riset Kesehatan Vol 3 No 1 (2023): Edisi Oktober
Publisher : RSUD Dr. Saiful Anwar Province of East Java

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/jk-risk.03.1.4

Abstract

Diabetic Retinopathy (RD) is the main cause of blindness in people of productive age worldwide. Poor control of hyperglycemia and blood pressure are essential risk factors for the development of RD. This condition will trigger the occurrence of biomolecular mechanisms that cause damage to vessels and cells in the retina and develop into RD. The early stages of RD are generally asymptomatic, so it is recommended to perform RD screening as soon as the patient is diagnosed with type 2 DM and every 5 years for type 1 DM patients. RD therapy can be carried out with a non-pharmacological and pharmacological approach that is applied based on the level of severity to minimize the progression of RD. Apart from conventional therapy, there are potential therapies in the future, which include oral pharmacological therapy, genetic therapy, stem cell therapy, and CRISPR-Cas-Based therapy.
Co-Authors Ulfayani, Nabila